Nuwamba 8, 2020/Kwalejin Likita, Jami'ar Tibet/Biology na Magunguna

Rubutu/Wu Tingyao

Za a iya ɗaukar masu ciwon dajiGanoderma lucidumyayin karbar niyya far?Da fatan rahoton bincike na gaba zai iya ba da wasu amsoshi.

Gefitinib (GEF) yana daya daga cikin mahimman magungunan da ake nufi don maganin ci gaba da ciwon daji marasa ƙananan ƙwayoyin cuta (ciki har da adenocarcinoma na huhu, ciwon huhu na huhu, da kuma ciwon huhu na huhu), yana kawo kyakkyawan fata ga marasa lafiya waɗanda suna tsira a cikin duhu.Amma hasken da ke fitowa daga ramin ba koyaushe zai kasance a kunne ba, saboda juriya na miyagun ƙwayoyi yana tasowa bayan watanni goma zuwa goma sha shida na jiyya.

Sabili da haka, idan za mu iya amfani da lokaci don inganta tasirin magani na GEF, yi ƙoƙarin magance ciwon huhu na huhu zuwa yanayin da ya fi dacewa da kulawa ko ma rage tasirin magunguna don marasa lafiya su sami yanayin jiki mai kyau don magance su. ciwon daji, watakila akwai damar da za a sa hasken rayuwa ya haskaka da haske.

Masu bincike daga Sashen Oncology na asibitin Yantai na likitancin gargajiya na kasar Sin da Kwalejin Kiwon Lafiya ta Jami'ar Tibet tare sun buga wani rahoton bincike a cikin "Pharmaceutical Biology" a karshen shekarar 2020 wanda ya tabbatar da gwajin dabbobi cewa ga mafi yawan huhu adenocarcinoma a cikin marasa kanana. cell huhu cancer, da hade amfani daGanodermalucidumtriterpenoids (GLTs) da GEF na iya hana haɓakar ƙwayar cuta yadda ya kamata da kuma rage tasirin magunguna, samar da sabon tsarin da ya dace da la’akari da dabarun jiyya masu alaƙa.

Masu binciken sun fara dasa layukan salula na alveolar adenocarcinoma na mutum (Layin salula na A549) a ƙarƙashin fata na beraye tare da lalata tsarin rigakafi.Bayan da diamita na subcutaneous ciwace-ciwacen daji sun kasance kusan 6-8 mm, sun fara ciyarwaGanoderma lucidumtriterpenoids (GLT, 1 g/kg/day), gefitinib (GEF, 15 mg/kg/ day) ko hade da duka na tsawon kwanaki 14, kuma gwajin ya kare a ranar 15th.Sai ya zama cewa:

(1) Inganta ƙimar haɓakar ƙari

GLTs da GEF na iya hana ci gaban huhu adenocarcinoma ciwace-ciwacen daji, amma haɗuwa da biyu yana da sakamako mafi kyau (Hoto 1 ~ 3).

Hoto 1 Tumors da aka fitar daga huhu adenocarcinoma mice a ƙarshen gwajin

Hoto 2 Canje-canje a cikin ci gaban ƙwayar cuta na huhu adenocarcinoma mice yayin gwajin

Hoto 3 Ƙimar haɓakar haɓakar ƙwayar ƙwayar cuta na huhu adenocarcinoma mice ta hanyoyin magani daban-daban

2) Ƙarfafa hana ƙwayar ƙwayar cuta angiogenesis da inganta ƙwayar cutar ciwon daji

Ciwon daji yana buƙatar ƙirƙirar sabbin tasoshin don ci gaba da girma.Sabili da haka, yawan ƙananan ƙwayoyin cuta a cikin ƙwayoyin tumor ya zama maɓalli mai mahimmanci ga ci gaban ciwace-ciwacen daji.Hoto na 4 (A) yana nuna rarraba microvessels a cikin sassan ƙwayar ƙwayar cuta na kowane rukuni.Hoto na 4 (B) yana nuna cewa haɗin GLTs da GEF yana da sakamako mai hanawa fiye da biyu kadai.

Hoto 4 Sassan nama na Tumor da ƙananan microvessel na huhu adenocarcinoma mice

A wasu kalmomi, haɗuwa da GLTs da GEF na iya toshe ƙarin ƙwayar ƙwayar cuta daga samun abubuwan gina jiki da kuma sa ciwace-ciwacen daji ya fi wuyar girma.Wannan tsarin aikin ya fito ne daga ƙaƙƙarfan ƙa'idodin ƙayyadaddun maganganu masu alaƙa da ƙwayar furotin a cikin ƙwayoyin tumor, ciki har da hana "mai karɓa na 2 (VEGFR2)" da kuma inganta samar da "Angiostatin" da "endostatin".

Bugu da ƙari, masu binciken kuma sun lura a cikin sassan ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar kuma kuma za ta karu sosai yayin da ƙwayar furotin (Bcl-Bcl). 2) wanda ke hana apoptosis na kwayoyin cutar kansa zai ragu.Kwayoyin adenocarcinoma na huhu suna hanzarta haɓakawa zuwa ga alkiblar apoptosis a cikin wannan ƙari da rage ƙarfi.

(3) Rage illolin kwayoyi

huhu adenocarcinoma berayen da aka bi da su kawai tare da GEF sun sami mafi yawan asarar nauyi;a gefe guda, haɗin GLTs da GEF zai iya mafi kyau kula da nauyin jikin huhu adenocarcinoma mice ── mafi kusa da na al'ada mice (kungiyoyin kula da al'ada) (Hoto 5).

Bugu da ƙari, huhu adenocarcinoma mice kawai da aka bi da su tare da GEF sun nuna damuwa, gajiya, barci, rage yawan aiki, rage yawan ci da fata maras kyau.Duk da haka, waɗannan sharuɗɗan sun fi sauƙi ko ba a bayyane ba a cikin ƙungiyar da aka bi da su tare da haɗin GLTs da GEF.Babu shakka, GLTs na iya gyara illolin da GEF ke haifarwa.

Hoto 5 Rarraba bayanan nauyi da canje-canje a cikin huhu adenocarcinoma mice yayin gwajin

(4) Amintaccen GLTs

Don kimanta amincin GLTs, masu binciken sun haɓaka layin sel na alveolar epithelial na al'ada na al'ada BEAS-2B da layin kwayar halittar adenocarcinoma na ɗan adam A549 da aka yi amfani da su a gwaje-gwajen dabba tare da GLTs a cikin vitro na awanni 48.

Ana nuna sakamakon a cikin Hoto 6. Lokacin da GLTs (mahimmanci na 2.5 da 5 mg / L) sun hana adadin rayuwa na huhu adenocarcinoma sel zuwa 80-60%, ƙwayoyin al'ada suna da rai;ko da a babban taro, GLTs har yanzu suna bi da ƙwayoyin kansa a fili da sel na al'ada daban-daban, kuma wannan bambancin ya ma fi GEF (Figure 7).

Hoto 6 Tasirin hanawa na GLTs akan haɓakar tantanin halitta

Hoto 7 Sakamakon hanawa na gefitinib akan ci gaban kwayar halitta

Dangane da binciken mai binciken, ƙimar IC50 na GLTs a 48 h na jiyya don layin salula na A549 shine 14.38 ± 0.29 mg / L yayin da GLTs ya nuna ƙarancin tasirin cytotoxic akan layin BEAS-2B tare da ƙimar IC50 na 78.62 ± 2.53 mg/L, wanda ke nufin cewa lokacin da GLTs ke mutuwa ga ƙwayoyin cutar kansa, har yanzu suna iya kiyaye babban matakin aminci ga ƙwayoyin al'ada.

GLTs da maganin da aka yi niyya suna tafiya tare da hannu, yana sa jiyya ta fi dacewa.

Wannan rahoton bincike ya nuna mana:

A ƙarƙashin yanayin gwaji guda ɗaya, gudanar da baki na GLTs bazai sami tasiri iri ɗaya na hanawa akan ciwace-ciwacen daji na adenocarcinoma na ɗan adam kamar GEF, amma GLTs ba su da wani sakamako na GEF.

Lokacin da GLTs da GEF ke aiki tare, ba za su iya kawai ƙara tasirin hanawa akan ci gaban ƙwayar cuta ba amma kuma rage tasirin gefitinib akan nauyi, ruhu, kuzari, ci da fata.Wannan shine abin da ake kira "ƙaramar haɓakawa da rage yawan guba".

Dalilin da ya sa GLTs na iya inganta GEF ta hana ƙwayar cutar adenocarcinoma na huhu yana da alaƙa da "hana angiogenesis na ƙari" da "inganta apoptosis cell ciwon daji".

Don tantance cutar kansar ɗan adam a cikin dabbobi, masu binciken sun yi amfani da beraye da tsarin rigakafi marasa lahani (ta yadda ƙwayoyin cutar kansar ɗan adam za su iya girma akan nau'ikan nau'ikan daban-daban).Sabili da haka, sakamakon shine ainihin tasirin GLTs da GEF kanta akan ƙwayoyin ciwon daji.

Duk da haka, a cikin ainihin aikace-aikacen maganin ciwon daji, aikin tsarin rigakafi dole ne ya shiga.Saboda haka, ban da GLTs da GEF, idan an ƙara "kyakkyawan rigakafi", shin sakamakon zai kasance mai daukar ido?

Masu binciken ba su ba da cikakken bayani game da GLTs da aka yi amfani da su a gwajin ba, amma bisa ga bayanin takardar, ya kamata ya zama ɗanyen da aka cire na GLTs iri-iri.Amma ingantaccen kashi na gram ɗaya a kowace kilogiram na nauyin jiki a cikin beraye a zahiri yana da yawa.Wannan yana gaya mana cewa aikace-aikace masu amfani na iya buƙatar ɗimbin kashi don yin tasiri.A gefe guda, yana kuma ba mu fata cewa a nan gaba yana iya yiwuwa a sami mahimman kayan aikin da za su iya aiki da kyau ko mafi kyau a ƙananan allurai.

A kowane hali, aƙalla wannan bincike ya nuna cewa triterpenoids daga Ganoderma lucidum ba wai kawai ba ya hana maganin magungunan da ake amfani da su na asibiti amma har ma yana da tasiri mai kyau na "ƙaramar inganci da rage yawan guba" bisa ga babban aminci.
Girma a cikin rami mai duhu yana buƙatar ƙarin hasken kyandir don jagoranci da haskakawa.Idan aka kwatanta da waɗancan “bege” waɗanda ba su isa ba ko da wahala a samarwa da yawa, ko “kayan girke-girke na sirri” tare da tushe da abubuwan da ba a san su ba,Ganoderma lucidumtriterpenoids, wanda za'a iya samu idan dai kuna so kuma sun tara ƙwarewar amfani na dogon lokaci, ya kamata ya fi dacewa da gwadawa.

[Madogararsa] Wei Liu, et al.Ganoderma triterpenoids attenuate ƙari angiogenesis a cikin huhu ciwon daji ciwon huhu tsirara mice.Pharm Biol.2020: 58 (1): 1061-1068.

KARSHE

Game da marubucin / Ms. Wu Tingyao
Wu Tingyao ta kasance tana ba da rahoto game da bayanan Ganoderma na farko tun 1999. Ita ce marubucin labarun Ganoderma.Waraka tare da Ganoderma(an buga a The People's Medical Publishing House a Afrilu 2017).
 
★ An buga wannan labarin ne a ƙarƙashin izini na musamman na marubucin.★ Wadannan ayyukan da ke sama ba za a iya sake su ba, cire su ko amfani da su ta wasu hanyoyi ba tare da izinin marubuci ba.★ Don keta bayanin da ke sama, marubucin zai bi alhakin da ya dace na shari'a.★ Asalin rubutun wannan labarin Wu Tingyao ne ya rubuta shi da Sinanci kuma Alfred Liu ya fassara shi zuwa Turanci.Idan akwai wani sabani tsakanin fassarar (Turanci) da na asali (China), asalin Sinanci zai yi nasara.Idan masu karatu suna da wasu tambayoyi, tuntuɓi marubuciyar asali, Ms. Wu Tingyao.